Liquid Biopsy
The Promise of a Blood Draw
A single tube of blood can contain circulating tumor DNA and other biomarkers of disease that enable early detection, guiding treatment decisions and identifying post-treatment stability or recurrence. While scientists worldwide are developing assays to unlock the full clinical potential of liquid biopsy testing, access to testing ultimately depends on preserving sample integrity through reliable blood collection and stabilization.
Why Liquid Biopsy Matters
Unlike tissue biopsy, liquid biopsy provides a dynamic, system-wide view of disease from a simple blood sample. This routine, minimally invasive approach enables longitudinal monitoring throughout therapy, detection of minimal residual disease (MRD), and holds strong promise for early cancer detection.
Where Performance Matters Most
Biomarkers in liquid biopsies are often present at extremely low concentrations and can be highly susceptible to degradation. Controlling preanalytical variables is therefore essential. Sample stabilization from point of collection to the time of testing — something standard blood tubes cannot provide — is critical to ensuring reliable results.
- Multi-site studies
Accommodating the draw
location variability. - Decentralized collection
Navigating draw site distance
from collection to lab. - Batch processing
Enabling flexibility without
compromising performance.
It Starts With the Right Tube
Streck’s blood collection tube portfolio was built for liquid biopsy and cell-free biomarker workflows, preserving cfDNA, cfRNA, proteins and platelets at room temperature for up to seven days with no cold chain required. Whether you’re designing a workflow from scratch or scaling an existing assay into broader deployment, that stability enables consistent, trustworthy performance across sites and time points possible. That’s The Science of Trust®.
7 days
room temperature stability
30+ years
in pre-analytical innovation
Adopted in pan-cancer early detection programs worldwide
Partner With Us
Streck works directly with assay development teams and clinical laboratories to design stabilization workflows that are built to scale. Whether you’re optimizing a single biomarker or building toward a multi-analyte platform, our technical team brings deep pre-analytical expertise to every stage of development.
Industry Resources
Pre-analytical standardization is a field-wide challenge. These organizations are working to address it.
BloodPAC
Cross-industry consortium focused on liquid biopsy data harmonization and pre-analytical standards across institutions.
OpenOnco
Open-access oncology data and research resources supporting translational science.
